Compare iShares MSCI ACWI ETF (ACWI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). Which is the better fit depends on your goals.
| ACWI | MEDP | |
|---|---|---|
52-Week High | $161.44 | $620.59 |
52-Week Low | $132.04 | $393.42 |
Market Cap | — | $16.90B |
Sector | — | Technology |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.65, up 0.34% today, with strong technical momentum showing bullish moving average signals. The ETF benefits from robust global earnings growth and investor inflows into equity ETFs, particularly in technology sectors. Recent institutional activity includes Bank of New York Mellon adjusting its position, while technical indicators show overbought conditions with RSI above 74.
The outlook remains positive given strong EPS growth and reasonable valuation at 15.5x forward P/E. Key risks include overbought technical conditions and market concentration in technology. Institutional sentiment appears constructive with continued ETF inflows supporting the global equity rally.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
